2021年2月04日Julie Liu 离开辉瑞加入 Cerecin，担任研发、化学、制造和控制部门新副总裁

2020年12月17日首例患者入组 Cerecin Tricaprilin 预防偏头痛 II 期试点临床试验（Relief 研究）

2020年11月04日Cerecin 宣布在 2020 年 CTAD 上展示 Tricaprilin 相关数据

2020年10月29日Cerecin 宣布 Tricaprilin 已成功获得美国 FDA 批准，成为治疗婴儿痉挛指定孤儿药

2020年10月08日美国 FDA 授权 Cerecin 公司研究药物 Tricaprilin 作为罕见小儿疾病指定用药治疗婴儿痉挛

2020年7月30日Cerecin 在 2020 年阿尔茨海默病协会国际大会上公布了 Tricaprilin 的新数据

2020年7月29日2020 年 9 月以“步数”换记忆，携手 ADA 造福更多失智症患者

2019年12月20日Cerecin 任命生物技术资深人士Joseph S. Zakrzewski 为董事长

2019年11月4日Bruce Morimoto加入Cerecin担任药物开发副总裁

2019年10月7日Lilian Chow出任Cerecin临床运营与监管事务副总裁

2019年1月7日Cerecin任命曹晓平博士为CMC负责人

2018年12月11日Cerecin赞助并出席“阿尔兹海默氏症疗法：淀粉样蛋白的替代疗法”研讨会

2018年10月24日Cerecin任命新加坡资深医药经理人陈珠珊为商业战略总监

2018年10月16日Cerecin在宣布成立新加坡新总部后任命两名科学咨询委员会新成员

2018年10月4日Accera完成由亚洲领先的农业综合企业丰益国际领投的新一轮融资并更名为Cerecin

2018年9月12日Cerecin总裁兼首席执行官Charles Stacey博士被任命为医学事务认证协会（ACMA）理事会成员

2017年7月12日Accera与韩国DuChemBio签署战略合作伙伴和独家授权协议

2017年5月4日Accera任命Judith Walker担任医药总监

February 28, 2017Accera Announces Results of its First Phase 3 Study in Mild-to-Moderate Alzheimer's Disease

November 30, 2016Beyond the Failed Beta Amyloid Hypothesis

September 26, 2016Accera to Present at Upcoming Healthcare and Investor Conferences

September 8, 2016Accera Appoints Jeffrey Cummings and Bruno Vellas to Scientific Advisory Board

August 2, 2016Accera Appoints C. Evan Ballantyne as Chief Financial Officer

May 12, 2016Accera Completes Enrollment of Phase 3 NOURISH AD Study of AC-1204 for Alzheimer's Disease Treatment

April 27, 2016Broomfield Biotech Firm Accera Moves to Boulder

April 20, 2016Bioscience roundtable: Attracting development capital, talent top of mind in Colorado

March 10, 2016Accera to Present at BIO Asia International Conference

March 8, 2016Accera Appoints Ernest Wong, Ph.D., as Head of Corporate Development

September 17, 2015Accera Supports World Alzheimer's Day

July 14, 2015Accera Reaches 75% Enrollment in the Phase 3 NOURISH AD Study of AC-1204 for the Treatment of Alzheimer's Disease

June 10, 2015Accera Appoints Dr. Charles Stacey, M.D., as President and CEO

February 20, 2015Dr. Samuel Henderson, Accera's V.P. of Research and Development, to Present at the 249th American Chemical Society National Meeting

January 14, 2014Accera statement on FDA warning letter

November 12, 2013Accera, Inc. to Moderate Symposium on Metabolic Dysregulation in Alzheimer's Disease During the 6th Annual Clinical Trials Conference on Alzheimer's Disease (CTAD)

October 28, 2013Accera, Inc. Announces Publication of Results in the Journal Neuropsychiatric Disease and Treatment of a Retrospective Cohort Study Examining the Effects of Axona® in Patients With Mild-to-Moderate Alzheimer's Disease

April 9, 2013Accera and the University of Miami Miller School of Medicine Announce Collaboration to Study Axona® for Cognitive Impairment in Patients with Multiple Sclerosis

March 1, 2013Accera, Inc. Introduces Axona® Patient Starter Kits for Alzheimer's Disease Patients Beginning Therapy

October 5, 2010Accera, Inc. Appoints Dr. Thomas Werner President & CEO and Announces FDA Acceptance of IND Application for AC-1204 for Mild-to-Moderate Alzheimer's Disease

March 9, 2010New Evidence Further Validates Ketone Body Therapy as an Effective Approach in Managing Alzheimer's Disease

February 1, 2010Accera, Inc. to Present at the 3rd Annual European Life Science CEO Forum for Partnering & Investing

November 23, 2009Tips for Caregivers and a New Therapy Offers Hope in the Fight Against Alzheimer's

November 17, 2009Accera, Inc. Announces Culmination of Lost & Found Campaign: Company Donates '$'25,000 to the Alzheimer's Foundation of America for National Memory Screening Day

November 11, 2009Accera, Inc. Awarded "Company of the Year" by the Colorado BioScience Association

November 11, 2009Accera, Inc. to Present at Lazard Capital Markets 6th Annual Healthcare Conference

September 18, 2009Accera Inc. to Present at UBS Global Life Sciences Conference

August 12, 2009Accera Announces Peer-Reviewed Publication of the Results of its 90-day Clinical Study of AC-1202 (Axona™) in Mild to Moderate Alzheimer's Disease

August 11, 2009Accera, Inc. to Support the Alzheimer's Foundation of America's National Memory Screening Day through On-line Awareness Effort

July 27, 2009Accera, Inc. Announces Dr. Gunnar Weikert Elected to Board of Directors

July 14, 2009Evidence for a New Genetic Link to Therapeutic Efficacy for Alzheimer's Disease

April 15, 2009Accera, Inc. Launches Neuera Pharmaceuticals, Inc.

March 25, 2009Accera, Inc. to Present at Upcoming Investor Conferences

March 24, 2009Dr. Thomas Werner Elected to Accera, Inc.'s Board of Directors

March 2, 2009Accera Launches Axona™, First Medical Food Therapy to Help Manage Mild-to-Moderate Alzheimer's Disease

February 19, 2009Accera, Inc. Sponsors Alzheimer's Association's 2009 ICAD Conference

2021年5月27日专访：Cerecin 公司在治疗偏头痛和婴儿痉挛方面的进展和扩张

PharmaBoardroom 和 Cerecin 总裁兼首席执行官 Charles Stacey 专访

2019年2月1日采访：阿尔兹海默氏症的临床需求缺口最大

BioSpectrum Asia对Cerecin总裁兼首席执行官Charles Stacey的采访

2018年10月24日采访：大脑和医药

《亚洲健康投资》（HealthInvestor Asia）对Cerecin总裁兼首席执行官Charles Stacey的采访

2016年11月28日Interview – Accera next up in Alzheimer's disease

2016年11月28日So long to Sola; Lilly bloom's hope withers big pharma continues to ‘Chase' AD dream

2016年5月5日Nestlé Wants to Sell You Both Sugary Snacks and Diabetes Pills

2015年7月2日Accera Hoping for an Alzheimer's Breakthrough

June 24, 2015Accera Pivots From Medical Foods to Potential Drug for Alzheimer's

Administering tricaprilin after a meal optimises bioavailability and minimises adverse events
Judith Anne Walker*, MD; Lars Nelleman,*MD; Lilian Chow*, MRDM; Bruce Morimoto**, PhD
Clinical Trials on Alzheimer’s Disease 2020

Tricaprilin shows similar PK, safety and tolerability in Caucasians and Chinese
Bruce H. Morimoto**, PhD; Lilian Chow*, MRDM; Lars Nelleman,*MD; Judith Anne Walker*, MD
Clinical Trials on Alzheimer’s Disease 2020

An evidence-based risk-mitigation approach to study design in APOE4(-) mild to moderate AD
Judith Anne Walker*, MD; Lars Nelleman,*MD; Bruce H Morimoto**, PhD; Lilian Chow*, MRDM
Clinical Trials on Alzheimer’s Disease 2020

Novel formulation AC-SD-03 of tricaprilin leads to excellent PK and safety in doses up to 30g BID
Lilian Chow*, MRDM; Lars Nelleman*, MD; Bruce H. Morimoto**, PhD; Judith Anne Walker*, MD
Clinical Trials on Alzheimer’s Disease 2020

Development of tricaprilin, a ketogenic drug for Alzheimer's disease
Judith Anne Walker*, MD; Lars Nelleman,*MD; Lilian Chow*, MRDM; Samuel T Henderson**, PhD
Alzheimer's Association International Conference 2020

The rat as a model for CER-0001 formulation development
Samuel T Henderson, PhD, Ameet Ambarkhane PhD, Bruce Morimoto, PhD, and Judith Walker, MD
Alzheimer's Association International Conference 2020

A Review of Ketogenic Therapies for Alzheimer’s Disease
S. Henderson
Metabolic Health Summit 2019

9–12 November, 2021Clinical Trials on Alzheimer's Disease conference (CTAD)

19–23 October, 20217th Global Symposium on medical ketogenic dietary therapies

September 8 – 12, 2021IHC 2021 – International Headache Congress – IHS and EHF joint congress 2021

26-30 July, 2021Alzheimer's Association International Conference (AAIC)

13-15 July, 2021Healthy Ageing APAC Summit

7–8 July, 2021DIA-CoRE Singapore Annual Meeting 2021

27 June–1 July, 2021DIA 2021 Global Annual Meeting

10-13 June 202113th Asian and Oceanian Epilepsy Congress (AOEC)

28-30 April, 20214th Annual Neuroscience Innovation Forum

25-28 April, 2021The World Orphan Drug Congress USA 2021

17–21 April, 2021American Academy of Neurology Annual Meeting (AAN Annual Meeting)

17–25 March, 2021Online Migraine World Summit 2021

8-10 October, 2020International Congress of the Asian Society against Dementia, ASAD 2020 Virtual Meeting

13-14 October, 2020Precision in Clinical Trials Virtual Summit

15 October, 2020Solebury Trout Virtual Private Company Showcase

11-13 November, 2020TIDES Europe: Oligonucleotide & Peptide Therapeutics

8-10 December, 2020Phar-East 2020
Virtual